Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR7 | P34969 | 4/20 | 0.63 |
| ▸ | HTR1A | P08908 | 7/20 | 0.54 |
| ▸ | DRD2 | P14416 | 3/20 | 0.54 |
| ▸ | HTR2A | P28223 | 3/20 | 0.54 |
| ▸ | HTR6 | P50406 | 1/20 | 0.54 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.54 |
| ▸ | FAAH | O00519 | 3/20 | 0.53 |
| ▸ | DRD3 | P35462 | 3/20 | 0.53 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4515279 | 0.92 | KDM4E (0.58) | HTR7HTR1ADRD2HTR2AHTR6 | |
| SCHEMBL3205704 | 0.88 | HTR7 (0.62) | HTR7HTR1ADRD2HTR2AHTR6 | |
| SCHEMBL3187810 | 0.87 | HTR7 (0.63) | HTR7HTR1ADRD2HTR2AHTR6 | |
| SCHEMBL3198757 | 0.87 | HTR7 (0.54) | HTR7HTR1ADRD2HTR2AHTR6 | |
| SCHEMBL3194779 | 0.87 | HTR7 (0.55) | HTR7HTR1ADRD2HTR2AHTR6 | |
| SCHEMBL3187888 | 0.86 | KCNH2 (0.74) | HTR7HTR1ADRD2HTR2AHTR6 | |
| SCHEMBL3187219 | 0.86 | OPRM1 (0.64) | HTR7HTR1ADRD2HTR2AHTR6 | |
| SCHEMBL3230486 | 0.86 | HTR7 (0.59) | HTR7HTR1ADRD2HTR2AHTR6 | |
| SCHEMBL3189295 | 0.85 | HTR7 (0.50) | HTR7HTR1ADRD2HTR2AHTR6 | |
| SCHEMBL3198969 | 0.85 | KCNH2 (0.72) | HTR7HTR1ADRD2HTR2AHTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100029682-A1 | NOVEL CHROMENE AND THIOCHROMENE CARBOXAMIDE DERIVATIVES, METHODS FOR PREPARING SAME AND THERAPEUTIC APPLICATIONS OF SAME | PIERRE FABRE MEDICAMENT (FR) | 2010-02-04 | — | — | US | claimed |
| US-20100029682-A1 | NOVEL CHROMENE AND THIOCHROMENE CARBOXAMIDE DERIVATIVES, METHODS FOR PREPARING SAME AND THERAPEUTIC APPLICATIONS OF SAME | PIERRE FABRE MEDICAMENT (FR) | 2010-02-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029682-A1 | NOVEL CHROMENE AND THIOCHROMENE CARBOXAMIDE DERIVATIVES, METHODS FOR PREPARING SAME AND THERAPEUTIC APPLICATIONS OF SAME | DRD3, CHRNA3, CHRM3 | HTR7 119/4885HTR1A 66/4885DRD2 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.